...
首页> 外文期刊>Frontiers in Surgery >Ponseti Casting vs. Soft Tissue Release for the Initial Treatment of Non-idiopathic Clubfoot
【24h】

Ponseti Casting vs. Soft Tissue Release for the Initial Treatment of Non-idiopathic Clubfoot

机译:Ponseti铸造与软组织释放,用于初始治疗非特发性的Clubfoot

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Ponseti casting has universally been accepted as the gold standard for treatment of idiopathic clubfoot. Conversely, primary treatment for non-idiopathic clubfoot has not been established. The purpose of this study is to compare treatment outcomes following primary soft tissue release (STR) and Ponseti casting of non-idiopathic clubfoot. Methods: An IRB-approved retrospective study of patients treated for non-idiopathic clubfoot between 2005 and 2020 was conducted. Patients were included if they began treatment before the age of 2 and had at least 1 year of follow up. Patients were placed into either the STR group or Ponseti group and variables of interest were documented including reoccurrence of deformity, number of surgeries performed, type of surgeries performed, anesthesia time, and surgery time. Data was analyzed using Mann-Whitney U test for continuous variables. Results: A total of 33 children with 57 neuromuscular/syndromic clubfoot were identified of which 9 (15 feet) were treated with STR and 24 (42 feet) were treated with Ponseti casting. Average anesthesia and surgery time were found to be 291 and 179 min, respectively, for the STR group, and 113 and 67 min for the Ponseti group. The difference in operating time was determined to be significant ( p = 0.02, p = 0.01). Patients treated with STR were found to have significantly more surgeries performed over the course of treatment than those treated with Ponseti casting ( p = 0.001) with an average of 4.2 surgeries in the STR group and 1.5 surgeries in the Ponseti group. Extracapsular procedures were performed in 100% of the STR group and 97.6% of the Ponseti group ( p = 0.55). Intracapsular procedures were performed in 100% of the STR group and 50% of the Ponseti group ( p = 0.001). Conclusion: The Ponseti method should serve as the primary approach in the initial treatment of non-idiopathic clubfoot as it can reduce the risk of future invasive intracapsular surgery and shorten anesthesia and surgery times when surgical treatment is necessary. Level of Evidence: Level III retrospective case control study.
机译:目的:Ponseti铸造普遍被接受为治疗特发性生命职业的金标准。相反,尚未建立非特发性疗法脚足的主要治疗。本研究的目的是在原发性软组织释放(STR)和非特发球菌刚性的Ponseti铸造后比较治疗结果。方法:进行2005年至2020年在2005和2020之间治疗的非特发性嗜睡蹄血管患者的IRB批准的回顾性研究。如果他们在2岁之前开始治疗,并且至少有1年的跟进,则包括患者。将患者置于STR组或Ponseti组中,并记录了感兴趣的变量,包括再发性的畸形,进行的手术数量,进行的手术类型,麻醉时间和手术时间。使用Mann-Whitney U测试进行分析数据,用于连续变量。结果:鉴定了33例患有57个神经肌瘤/综合组织蹄螨的儿童,其中9名(15英尺)用STR,24(42英尺)用Ponseti铸造处理。对于Ponseti组的STR组分别发现平均麻醉和手术时间为291和179分钟,以及113和67分钟。操作时间的差异决定是显着的(p = 0.02,p = 0.01)。发现患有STR的患者在治疗过程中进行了显着更多的手术,而不是用Ponseti铸造(P = 0.001)处理的那些,平均4.2个在Ponseti组中的4.5手术中的4.2手术。肌涂层程序在10%的STR组中进行,97.6%的Ponseti组(P = 0.55)。在100%的STR组和50%的PONETI组中进行骨囊手术(P = 0.001)。结论:Ponseti方法应作为非特发球菌初期治疗的主要方法,因为它可以降低未来侵入性骨科手术的风险,并且在外科治疗需要时缩短麻醉和手术时间。证据级别:第三级回顾性案例控制研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号